期刊文献+

文拉法辛缓释剂治疗抑郁症的开放性研究 被引量:38

The efficacy and safety of venlafaxine XR in treating patients with major depression in a multicenter,open-label,16 week study
原文传递
导出
摘要 目的 观察文拉法辛缓释剂(商品名:怡诺思)治疗抑郁症16周的疗效和不良反应。方法 采用开放性多中心研究方法,对350例符合国际疾病分类第10版抑郁障碍诊断标准的住院或门诊患者,进行可变剂量文拉法辛缓释剂治疗,共16周。分别于治疗前和治疗后第2,4,8,12和16周末评定17项汉密尔顿抑郁量表(HAMD17)、14项汉密尔顿焦虑量表(HAMA14)和临床疗效总评量表(CGI)及药物疗效,记录治疗中出现的不良反应。结果 321例完成16周治疗。(1)从治疗第2周末至第16周末,HAMD17总分和各因子分均低于治疗前[基线和第16周末的HAMD17总分分别为(28.04±7.9)分和(4.2±3.9)分;P〈0.001]。治疗第16周末,HAMD17总分减分率达85%,216例(67.3%)患者达到临床治愈(HAMD17总分≤7分),315例达到治疗有效,有效率(HAMD17减分率≥50%的例数占所完成研究例数的比例)为98.1%。(2)反复发作者的药物剂量自第2-16周均明显高于单次发作者(P〈0.05),病程〈1年的患者其疗效[抑郁因子分为(1.72±1.91)分]优于病程≥1年的患者[(2.004±2.26)分;P〈0.05]。(3)73例(20.8%)患者出现不良反应,多为中枢神经系统和消化系统反应,如头晕,多汗和恶心等。治疗前后患者的血压无明显改变。结论 文拉法辛缓释剂是一种较为安全有效的抗抑郁药,适合长期治疗以预防抑郁症的复发。 Objective The aim of this naturalistic open-label study was to contribute further information on the long-term efficacy and tolerability of venlafaxine extended releasing form in Chinese patients with major depression. Methods A multi-center, open-label study was specifically designed to prospectively understand the efficacy and safety of flexible dose of venlafaxine in treating major depression for 16 weeks. All patients met the ICD-10 criteria for depressive disorders and were assessed with the Hamilton Depression Rating Scale ( HAMD), Hamilton Anxiety Rating Scale ( HAMA), Clinical Global Impression (CGI) and side effects, including the lab test and blood pressure, at baseline and on weeks 2, 4, 8 12 and 16. Results Altogether 350 patients were enrolled in the study, with 144 males and the mean age of 37 years old. In 321 patients who completed 16 week treatment, significant reductions in HAMD and HAMA, and subscale of HAMD scores were seen from baseline on week 2 and continuing to week 16, and 67.3% of patients were clinical remission (total score of HAMD ≤7). The dosage in patients with recurrent episodes was higher than that with first episode, and the efficacy in acute patients was better than in chronic patients. The common side effects were temporal dizziness, vomit and hyperhidrosis. There were not significant changes for the blood pressure after treatment. Conclusion The extended releasing venlafaxine is an efficient antidepressant with better tolerability, it is suitable for long-term preventive treatment.
出处 《中华精神科杂志》 CAS CSCD 北大核心 2006年第2期85-89,共5页 Chinese Journal of Psychiatry
关键词 抗抑郁药 治疗结果 药物评价 迟效制剂 文拉法辛 Antidepressive agents Treatment outcome Drug evaluation Delayed-action preparations Venlafaxine
  • 相关文献

参考文献13

  • 1Van Londen L, Molenaar RP, Goekoop JG, et al. Three- to 5-year prospective follow-up of outcome in major depression. Psychol Med,1998, 28:731-735. 被引量:1
  • 2Gutierrez MA, Stinmael GL, Aiso JY. Venlafaxine: a 2003 update.Clin Ther, 2003, 25:2138-2154. 被引量:1
  • 3Stahl SM. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J Clin Psychiatry, 1998,59 Suppl 18:23-29. 被引量:1
  • 4Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry, 1991,48:851-855. 被引量:1
  • 5The World Health Organization. The world health report 2004 : annex table 3 burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimate for 2002, Geneva : World Health Organization, 2005. 127-131. 被引量:1
  • 6Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry, 1999, 60Suppl 22:7-11. 被引量:1
  • 7卫生部疾病控制司 中国疾病预防控制中心精神卫生中心 中华医学会精神病学分会.中国抑郁障碍防治指南[M].北京:北京大学精神卫生研究所,2003.27-54. 被引量:2
  • 8Kelsey JE. Achieving remission in major depressive disorder: the first step to long-term recovery. J Am Osteopath Assoc, 2004, 104(3 Suppl 3) :S6-10. 被引量:1
  • 9Montgomery SA, Mahe V, Haudiquet V, et al. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis. J Clin Psychopharmacol, 2002, 22:561-567. 被引量:1
  • 10Entsuah R, Gorman JM. Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. J Psychiatr Res,2002, 36:111-118. 被引量:1

共引文献1

同被引文献314

引证文献38

二级引证文献233

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部